NSTC First Friday Biosciences Seminar: “Stem Cells and Cellular Therapies – The Future Tools of Biological Research and Precision Medicine”

Friday, November 1 2013
12:30 pm – 2:00 pm

Location: 100 Cummings Center, Suite 221-E, Beverly, MA

The possibility of banking one’s own tissues represents an intriguing and potentially transformative proposition for both regenerative and personalized medicine – and dental pulp and periodontal ligament sourced stem cells continue to chart a rapidly advancing path. While recent advances in stem cell biology have dramatically evolved prospective scientific thinking, all stem cells regardless of source or ability have both advantages and challenges related to technical limitations, therapeutic capabilities, and relevant commercial adaptability. This seminar intends to provide a thorough understanding of the advantages and limitations of various stem cell sources – under the lens of how to provide the industry as a whole a viable path to commercialization.



Name: Joseph Laning, PhD
Title: Vice President R&D
Company:  Provia Laboratories, LLC

Bio: Dr. Joseph Laning Ph.D., Vice President of R&D at Provia Laboratories, LLC, has spent the past 18 years translating concepts into products in the fields of would care, regenerative medicine, and stem cell therapy. His current research interests center on the optimization of dental sourced MSC (DPSC) banking methods and the investigation of DPSC utility through differentiation.  

Prior to joining Provia, Dr. Laning served in leadership roles at Organogenesis, Inc., where he developed and implemented pre-clinical investigations as well as managed all patient immunology safety testing leading to the PMA approval of ApligrafTM, and at ViaCell, Inc. While at ViaCell, he served as Director of Therapeutic Development and then as Senior Director of Analytical Biology. In these roles he oversaw strategic and operational scientific plans leading to successful approval of both IND and IDE FDA filings and completion of the company’s cell therapy clinical trial in allogeneic cord blood stem cell transplantation.

Dr. Laning has also applied his extensive experience in scientific management and product development in his work as a scientific and business consultant. He has served as Executive Director of the Massachusetts Stem Cell Bank and Registry and as Research Associate Professor of Molecular Medicine at the University of Massachusetts Medical School.

Dr. Laning received his bachelor's degree in Biology from Boston University and his PhD in Immunology from Harvard University. He is an active member of the International Society for Cellular Therapy and serves as the ISCT delegate to the United States Pharmacopiel Convention.

Refreshments Served:   Pizza, salads, and soft drinks

Cost for Members and Non-members


Host:   BioBusiness Consulting, Inc., is a biobanking, clinical research and biotechnology advisory serving pharmaceutical, biotech, academic and government sectors worldwide. For more information please contact: Lisa Miranda, President and Chief Executive Officer, at lisabmiranda@biobusinessconsulting.com or 978-323-9834.

Share MassBio